Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANCAN trial of medicinal cannabis for chemotherapy-related symptoms in cancer
ACTRN12622000419763Phase 2Recruiting
- Sponsor
- Central Adelaide Local Health Network
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol and dronabinol in cancer, chemotherapy-induced gastrointestinal toxicity, stomatitis and 3 more (2 arms), sponsored by Central Adelaide Local Health Network. Primary endpoint: Gut distress by Mucositis Daily Questionnaire. Started Feb 2025; status: recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
cancerchemotherapy-induced gastrointestinal toxicitystomatitisdiarrheasleep disorder
Beyond the preview
Go deeper on ACTRN12622000419763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000419763.